Concerning the use of anti‐tumor necrosis factor (TNF), the cumulative probabilities at 1 and 5 years were not different between IBD‐PSC and matched‐IBD groups (8.3%, 95% CI, 2.1–29.4 and 12.5%, 95% CI, 7.3–21.0 at 1 year; 24.6%, 95% CI, 10.8–50.2 and 31.7%, 95% CI, 23.1–42.4 at 5 years, respectively) (see Figure 1C). Here, TNF is linked to inflammatory bowel disease.